LETTER TO THE EDITOR
Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome Sir, In 2000, a 20-year-old woman came to our attention with aphasia, transitory dysarthria, (CT scan compatible with stroke) and thrombocytopenia (platelet count 29 Â 10 9 /l). Laboratory tests revealed anticardiolipin antibodies (aCL) 328/ 15 U/l (ELISA kit Phadia, Uppsala, Sweden, EliA Cardiolipin IgG/IgM, normal value <40 U/l), antibeta-2 glycoprotein I antibodies 104/9 U/l (ELISA kit Phadia, Uppsala, Sweden, EliA ß2 Glycoprotein I IgG/IgM, normal value <40 U/l), and positivity for lupus anticoagulant (LAC). LAC measurement included: dilute Russell's viper venom time (dRVVT) (Hemosil, LA-screen/confirm, Instrumentation Laboratory, Lexington, USA), partial thromboplastin time-LA (PTT-LA) (Diagnostica Stago, Asnie`res, France), silica clotting time (SCT) (HemosIL TM , DiaPharma Group, Inc. Ohio, USA) and kaolin clotting time (KCT) (homemade, according to Exner). 1 If PTT-LA was prolonged, the hexagonal phospholipid neutralization test was performed as confirmatory (STACLOT-LA, Diagnostica Stago, Asnie`res, France). A diagnosis of primary antiphospholipid syndrome (APS) was made when antiphospholipid antibody (aPL) positivity was confirmed 3 months later. 2 Therapy with prednisone (50 mg/day) and intravenous immunoglobulins (IVIG, 400 mg/kg/ day for 5 days) was started, resulting in an increase in platelet count. Oral anticoagulation therapy (OAT) was started when the platelet count reached 60 Â 10 9 /l. Platelet levels increased up to 110 Â 10 9 /l within 4 weeks and remained stable between 130 and 140 Â 10 9 /l for 4 months, when they dropped again to 70 Â 10 9 /l. The patient was then treated with adjusted doses of prednisone (37.5 mg/day) and IVIG (400 mg/kg/day for five more days). Prednisone treatment was slowly tapered to a daily dose of 7.5 mg and finally discontinued in May 2007, when platelet counts were between 120 and 150 Â 10 9 /l.
In 2009, the patient presented with a worsening of thrombocytopenia (platelet count 40 Â 10 9 /l) and was treated with the same regime of IVIG, with partial response (platelet count up to 90 Â 10 9 /l). She relapsed within 3 weeks. Splenectomy was not performed due to the high risk of thromboembolic and/or haemorrhagic complications.
After ruling out possible contraindications, treatment with rituximab (RTX) was started at the conventional weekly dose of 375 mg/m 2 (days 1, 8, 15 and 22). Two more monthly doses after the last infusion (day 22) were administered, based on the protocol we employ for mixed cryoglobulinaemia with good results on long-lasting disease remission. 3 Prednisone treatment (daily dose of 10 mg at day 1) was tapered and finally discontinued 4 weeks after first RTX infusion. No other immunosuppressive drugs were associated. Treatment was well tolerated and no side effects were observed.
RTX administration led to an increase in the platelet count ( Figure 1 ). In addition, aCL, anti-beta2-GPI antibodies and LAC ratio were downregulated ( Figure 1 ).
In this case, RTX-induced downregulation of aPL was observed. It was associated with a significant improvement in thrombocytopenia, thus allowing OAT to be administered.
Successful amelioration of thrombocytopenia in APS after treatment with immunosuppressive therapy has previously been reported. 4 However, a non-negligible percentage of patients become resistant/non-responsive to immunosuppression, and sometimes splenectomy cannot be performed because of the high risk of bleeding and/or thrombotic events. Some authors have reported that RTX is effective in treating APS and reducing aPL, 5 but drug-induced aPL downregulation remains a challenge. 6 Notably, in a observational study in patients with systemic lupus erythematosus, RTX resulted in a significant reduction in levels of IgG aCL. 7 To our knowledge, this is the first report showing downregulation of aPL after RTX alone in a patient with primary APS who was not treated with immunosuppressive drugs prior to anti-CD20 antibody therapy. Some authors reported a close correlation between aCL titre reduction and an improvement in platelet count in patients with primary APS who were treated with RTX for thrombocytopenia. However, these findings were observed in refractory cases following previous immunosuppressive drug administration in addition to RTX. [8] [9] [10] Of note, a 4 plus 2 protocol of RTX administration was employed. 3 In our experience of treatment of idiopathic and secondary microscopic vasculitis, this scheme obtained more prolonged remissions, especially in mixed cryoglobulinaemia, where time to relapse was found to be delayed up to 54 months.
Moreover, it has been hypothesized that B-cells are involved in the aPL-induced clinical manifestations of the disease, 6 and it would be reasonable to assume that RTX alone (with no other immunosuppressant drug) may be useful in the management of APS. To date, after a 10-month followup period, the patient is well and her platelet count is within the normal range. OAT is ongoing.
Despite the limits related to the relatively short follow-up, this report may represent a starting point for further studies that could provide us with a better understanding of the mechanisms involved in the pathogenesis of aPL production.
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